ng expenses:Selling, general and administrative1,8165733,2881,956Payroll expense272325834849Consulting expense3534341,1061,009Operating expenses 2,4411,3325,2283,814Operating loss(2,024)(445)(2,687)(1,419)Other income-316Settlement income---1,250Interest expense (44)-(158)(2)Loss before income taxes(2,068)(442)(2,844)(165)Income tax benefit(866)(148)(1,108)(9)Net loss$
(1,202)$
(294)$
(1,736)$
(156)Loss per share:Basic and diluted$
(0.10)$
(0.03)$
(0.15)$
(0.01)Weighted average common shares outstanding:Basic and diluted11,81111,01111,64511,011Imagenetix, Inc. Condensed Consolidated Balance Sheets(Unaudited)(In thousands) December 31,
March 31, 2010 2010 Assets:Current assets:Cash and cash equivalents
$
171$
981Accounts receivable, net9591,049Inventories, net9881,350Prepaid expenses and other current assets282151Deferred tax asset2,034933 Total current assets4,4344,464Property and equipment, net 6789Long-term prepaid expenses918Other assets 117125 Total assets
$
4,627$
4,696Liabilities and stockholders' equity:Current liabilities:Secured note payable to bank
$
1,025$
-Convertible notes294-Accounts payable710997Accrued liabilities6783Customer deposits2225Contract payable7586 Total current liabilities2,1931,191Stockholders' equity 2,4343,505 Total liabilities and stockholders' equity
$
4,627$
4,696ContactImagenetix Investor Relations
William P. Spencer(858)385-2797
Chief Executive OfficerImagenetix, Inc.Tel: (858) 674-8455
'/>"/>
SOURCE Imagenetix, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine technology :1.
Letter to Shareholders From Imagenetix, Inc. President/CEO William Spencer2.
Imagenetix, Inc. Provides Net Sales Guidance for the Second Quarter Fiscal 20113.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound4.
Spherix Reports Second Quarter Earnings5.
Tapestry Reports Second Quarter 2007 Results6.
Callisto Reports on Second-Quarter 2007 Milestones7.
ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.8.
Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs9.
Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress10.
TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women11.
Biopure Reports on Meeting with the FDA